Study ID: 103369 Clinical Study ID: 103369 Study Title: A Randomized Phase III Study of Cisplatin Versus Cisplatin plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix Patient Level Data: Study Listed on Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: Topotecan Study Indication: Cancer 


  1. 3/14/19 3/14/19 -
  2. 12/31/19 12/31/19 -
Copyright Holder

GSK group of companies

Uploaded on

December 31, 2019


To request one please log in.


Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Cisplatin and Topotecan Recurrent or Persistent Carcinoma of the Cervix - 103369

Pathology Report

  1. StudyEvent: ODM
    1. Pathology Report
Administrative data
Primary Site
Histology Type
Carcinomas, All Sites
Sarcomas, All Sites
LMP Tumors of the Ovary
Sex Cord Stromal Tumors
Germ Cell Tumors
Histologic Grade
Histologic Grade of Primary Tumor
Specimens obtained from:
Specimen(s) obtained from:

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial